Onco Actu du 6 juin 2017

	2.6 Etiologie - Environnement
'Everyday chemicals' linked to cancer [NHS Choices] This study alone can't inform on a safe or toxic exposure level, either for people with or for people without BRCA2 mutations. We also can't conclude that aldehydes provide the whole answer as to why people with BRCA2 mutations are susceptible to cancer.
	4.12 Biopsies liquides
Grail’s $1 Billion Bet on the Perfect Cancer Test [MIT Technology review] Grail is now seeking 120,000 women to provide blood when they undergo mammograms at centers including the Mayo Clinic.
	4.2 Dép., diag. & prono. - Génome
Illumina and American Society of Clinical Oncology, Inc. Jointly Donate Thousands of Somatic Interpretations to CIViC to Advance Genomic Medicine [ASCO] This donation includes close to 2,000 predictive associations that were curated by Illumina for ASCO’s ground-breaking Targeted Agent and Profiling Utilization Registry (TAPUR™) clinical study.
	5.12.2 Immunothérapies - CAR-T
Moving on from a trial disaster, Juno reports positive data for JCAR017 — and a death [EndPoints] While only one patient suffered from severe cytokine release syndrome, which was not fatal, there were 8 cases — 18% of the total — of neurotoxicity.
	5.12.5 Immunothérapies - Pharma
How Did Bristol Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss [Forbes] Quite simply, Lynch says, it looks as if Merck’s predictive cutoff was “superior” to Bristol’s. No excuses, no mysteries.
A Hot Cancer-Drug Race Keeps Getting More Crowded [Bloomberg] Medicines that turn immune systems against tumors hold promise for patients, risks for investors.
	5.12.6 Immunothérapies - AMM
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy [BMS] Opdivo is the first and only Immuno-Oncology agent to receive European approval for the treatment of this type of bladder cancer.
	5.2.1 Pharma - Partenariats
Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII [EndPoints] This is just the first of what could potentially prove to be a series of late-stage studies for these two companies, which have also been running through trials on a range of indications focused on relapsed or refractory Hodgkin lymphoma and CD30-expressing relapsed or refractory non-Hodgkin lymphomas.
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer [Novartis] Brings Novartis innovation and breast cancer expertise together with IBM Watson Health proficiency in data analytics and machine learning.
Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and ADCETRIS® (Brentuximab Vedotin) in Pivotal Phase 3 Clinical Trial in Relapsed Hodgkin Lymphoma [BMS] Pivotal Phase 3 Trial Planned for mid-2017 will Evaluate ADCETRIS Alone or in Combination with Opdivo in Relapsed/Refractory or Transplant-Ineligible Advanced Classical Hodgkin Lymphoma.
Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies [BMS] QIAGEN and Bristol-Myers Squibb intend to develop GEPs for several Bristol-Myers Squibb I-O molecules under the initial agreement.
Novartis, IBM Watson Health team up for breast cancer project [Reuters] "We hope this collaboration also uncovers care efficiencies that can be applied beyond breast cancer."
	5.3 Traitements - FDA, EMA, NICE...
In cancer treatment, there’s more than one way to measure patient benefit [FDA Voice] It’s also important to recognize that the drug approval process does not end with the drug’s approval. This is just the beginning.
	5.4 Traitements - Economie
Debunking The Pharmaceutical Research ‘Free Rider’ Myth: A Response To Yu, Helms, And Bach [Health Affairs Blog] This claim that “everyone gets a free ride off us,” pushed so vigorously by pharmaceutical companies to the US public and policy makers, is simply not true. The claim has been made so often for so long that many hold it as an economic fact, even though no solid evidence is presented to back it up.
Drug Prices And Medical Innovation: A Response To Yu, Helms, And Bach [Health Affairs Blog] Essentially, the authors imply that the US price premium could be significantly reduced without affecting research and development investments or having other adverse effects. This is a strikingly bold and unfounded conclusion.
	5.5.2 ASCO (sein)
New gene therapy offers hope against incurable form of breast cancer [The Guardian] The study was the first to show olaparib can slow growth of inherited BRCA-related breast cancer.
	6. Lutte contre les cancers
Big returns on small cancer research investment, study suggests [Reuters] A government-backed research collaboration program started in the 1950s has added about 3.34 million years of life for cancer patients in the U.S. at an estimated cost of just $125 for each year of life gained based on successful new treatment options developed through the program, a new study estimates.
	6.1 Observation
Take a Number: Women With Aggressive Breast Cancer Are Living Longer [NY Times] “It’s difficult to know the contribution of early imaging on one hand and better treatment on the other,” said the lead author, Angela B. Mariotto.
	6.4 Médico-éco
The Specialists’ Stranglehold on Medicine [NY Times] Most Americans mistakenly believe that they must see specialists for almost every medical problem. What people don’t know is that specialists essentially determine the services that are covered by insurance, and the prices that may be charged for them.
	6.5 Médecines alternatives
Cassandra Callender’s cancer is progressing, and the quackery didn’t stop it. Let’s hope real medicine can. [Respectful Insolence] This is the sort of story that I really hate but feel obligated to discuss.
	6.6 Publications
Data sharing statements for clinical trials [BMJ] It is encouraging that data sharing is already occurring in some settings. Over the past year, however, we have learnt that the challenges are substantial and the requisite mechanisms are not in place to mandate universal data sharing at this time.